MIRA Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MIRA | BIIB | AZN | SMSPHARMA.BO | NMRA | QNTM | |
|---|---|---|---|---|---|---|
| Market cap | 23.57M | 37.61B | 293.14B | 48.32B | 106.35M | 14.21M |
| P/E (TTM) | — | 110.2 | 26.7 | 45.9 | — | — |
| Forward P/E | -1.4 | 15.6 | 16.7 | — | -0.9 | -0.3 |
| Price/book | 2.9 | 2.0 | 5.7 | 6.1 | 2.4 | 2.1 |
| Dividend yield | — | — | 1.69% | 0.08% | — | — |
| 1-year change | −61.04% | +62.35% | +12.81% | +80.88% | −78.21% | −74.27% |
| Today | +8.34% | +2.22% | +2.79% | −1.99% | −0.86% | 0.00% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All MIRA news ›MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
"We are entering an important stage for Ketamir-2 as we prepare to evaluate the drug for the first time in patients with persistent CIPN," said Erez Aminov, CEO of MIRA. "This marks the transition from establishing safety and…
Mira Pharmaceuticals initiated with a Buy at Maxim
Maxim analyst Jason McCarthy initiated coverage of Mira Pharmaceuticals (MIRA) with a Buy rating and $3.50 price target Published first on The... Mira Pharmaceuticals initiated with a Buy at Maxim Maxim analyst Jason McCarthy initiated…
From the 4Search news index, newest first.
In the news
Mentioned with
Most coverage from
- markets.businessinsider.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.